CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma.
HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究强调 HOXC6/8/10/13 参与免疫浸润,并在 GBM 中作为治疗靶点具有潜在的临床价值。
胶质母细胞瘤(GBM)以细胞增殖失调和免疫细胞浸润为特征,是中枢神经系统常见且致命的肿瘤。近年来,免疫细胞浸润作为潜在的GBM新型免疫治疗选择而受到关注。同源盒C簇(HOXC)是一个进化上保守的转录因子家族,参与胚胎发生和肿瘤发生。然而,HOXC与GBM预后及免疫浸润的相关性仍不明确。
从TCGA和GTEx数据库下载了带有相应临床特征的RNA-seq数据。使用单因素和多因素Cox回归计算HOXCs与临床特征之间的相关性。采用R语言及ggplot2、survminer、survival、GSVA和pROC包分析数据并呈现图表。使用MethSurv、UALCAN和cBioPortal评估GBM中HOXCs的DNA甲基化和突变状态。我们还在一组36例患者中通过qPCR和免疫组织化学验证了HOXCs的表达和预后。
我们发现HOXC6/8/10/13是GBM诊断和预后判断的关键生物标志物。基因集变异分析显示,HOXCs的表达水平与多种免疫细胞的浸润相关。qPCR和免疫组化数据验证了HOXC6/8/10/13在GBM中的预后价值。最后,基因本体论和京都基因与基因组百科全书通路分析表明,HOXCs可能参与DNA结合转录激活因子活性和apelin信号通路。
Glioblastoma (GBM), characterized by deregulated cell proliferation and immune cells infiltration, is a common and lethal tumor of the central nervous system. Recently, the infiltration of immune cells has attracted attention as a potential novel GBM immunotherapy option. Homeobox C cluster (HOXC) is an evolutionarily conserved family of transcriptional factors that are involved in embryogenesis and tumorigenesis. Nevertheless, the correlations of HOXCs with the prognosis and immune infiltration of GBM remain blurred.
The RNA-seq data with corresponding clinical characteristics were downloaded from TCGA and GTEx databases. The correlations between HOXCs and clinical characteristics were calculated using univariable and multivariate Cox regression. R language with ggplot2, survminer, survival, GSVA, and pROC packages were employed to analyze the data and present the plots. MethSurv, UALCAN and cBioPortal were employed to evaluate the DNA methylation and mutation status of HOXCs in GBM. We also verified the expression and prognosis of HOXCs by qPCR and immunohistochemistry in a cohort of 36 patients.
We identified that HOXC6/8/10/13 were crucial biomarkers for diagnosis and prognostic judgement in GBM. Gene set variation analysis revealed that levels of expression of HOXCs were associated with the infiltration of various immune cells. The qPCR and immunohistochemistry data validated the prognostic values of HOXC6/8/10/13 in GBM. Finally, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that HOXCs might be involved in DNA-binding transcription activator activity and the apelin signaling pathway.
This research highlights that HOXC6/8/10/13 are involved in the immune infiltrates, also provide potential clinical utility as therapeutic targets in GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。